Table 1.
Retrospective analyses involving the use of tocilizumab in patients with COVID-19.
| Author (year) | Country | Population (n) | Mean age | Male (%) | HTN (%) | DM (%) | Stroke (%) | COPD (%) | Symptoms > 20% | Critically ill (%) | Mean IL-6 level prior to TCZ (pg/mL) | TCZ dosing | Death (%) | Hospitalized (%) | Discharged (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Luo (2020) | China | 15 | 73 | 80 | 60 | 27 | 20 | 0 | NR | 47 | 111.05 | Range of 80-600 mg IV with average of 1.47 doses | 20 | 80 | NR |
| Xu (2020) | China | 21 | 57 | 86 | 43 | 24 | 5 | 5 | Fever (100%), Cough (67%), Phlegm (43%), Fatigue (29%), SOB (29%) | 19 | 132.38 | 400 mg IV x 1 dose | 0 | 10 | 90 |
Abbreviations: COPD: chronic obstructive pulmonary disease; DM: diabetes mellitus; HTN: hypertension; IL-6: interleukin 6; IV: intravenous; NR: not reported; SOB: shortness of breath; TCZ: tocilizumab.